Trustiva is an oral formulation that consists of three antiretroviral active ingredients- Efavirenz, Emtricitabine, and Tenofovir. These drugs work in combination to treat the HIV infection and HBV coinfection with HIV. This medication reduces the viral load in the body, maintains CD4 cell counts, and prevents progression to Acquired Immune Deficiency Syndrome (AIDS)
1. Infection by the retrovirus HIV
HIV affects the T-helper (CD4+) cells and destroys the immune system, making the body susceptible to opportunistic infections, which can lead to Acquired Immunodeficiency Syndrome (AIDS) if left untreated. Trustiva inhibits the rate of viral replication, which reduces the total amount of virus in the bloodstream. In this way, Trustiva preserves the function of the immune system.
2. Chronic Active Hepatitis B (Via properties of Tenofovir and Emtricitabine)
Chronic liver disease caused by the hepatitis B virus (HBV), which attacks the liver hepatocytes. Each infectious hepatocyte that is destroyed facilitates inflammatory processes and the formation of fibrosis within the liver, which eventually results in increased rates of cirrhosis or liver cancer. For this indication, Trustiva significantly inhibits the rate of viral replication, thereby limiting further liver cell damage.
3. Reduction of HIV Disease Progression and Complications
As the untreated HIV disease progresses, the body’s immune system continues to deteriorate. This causes the host to become susceptible to severe infections/malignancies. In such cases, timely antiretroviral therapy is essential. Trustiva systematically supports viral suppression, thus stopping the progression to the advanced stages of AIDS. It also improves the patient’s quality of life and the overall length of survival.
1. HIV-1 infection
Recommended dose:
Maximum dose limit:
Missed dose instructions:
Overdose instructions:
2. Chronic Hepatitis B
3. Prevention of HIV progression and complications
Recommended dose:
Trustiva is not routinely recommended just for Hepatitis B infection. However, it can be used for HBV-HIV coinfection with the following dosage
Missed dose instructions:
Overdose instructions:
During an HIV infection, the virus enters the CD4+ T-cells of the immune system. It utilizes the reverse transcriptase enzyme to convert the RNA into viral DNA, which is integrated into the human genome in later stages. Therefore, the virus continues to proliferate and infect other CD4+ T cells until all the target cells are infected.
Trustiva inhibits the viral multiplication process at a key stage by using three different antiretroviral compounds in combination therapy. The first agent is Efavirenz, which binds directly to HIV reverse transcriptase and inactivates it non-competitively. The second and third agents, Emtricitabine and Tenofovir, get incorporated into the viral DNA to terminate the formation of new viruses and inhibit viral replication.
This reduces the overall viral load in the body. As a result, use of Trustiva improves CD4+ T cell counts and preserves immune function, which prevents the development of severe complications due to HIV.
Common side effects (usually mild)
Neuropsychiatric effects (important)
Gastrointestinal effects
Liver-related effects
Kidney-related effects
Metabolic & systemic effects
Lactic acidosis (rare but serious)
Bone effects
Cardiac effects
Red flag side effects (seek urgent care)
Frequently Asked Questions
1.Can Trustiva cure HIV infection?
Trustiva can control the viral load in the body, but cannot completely cure the disease.
2.Can pregnant women consume Trustiva?
This medication must be given to pregnant women only if the benefits outweigh the risks.
3.Can I stop taking the medicine if symptoms are relieved?
Abruptly stopping Trustiva therapy can worsen the condition further.
4.Does Trustiva affect the bones?
Yes. Trustiva is associated with low bone density and risk of osteoporosis.
5.Does Trustiva prevent the risk of transmission?
Trustiva can reduce the risk of transmission, but it cannot completely prevent transmission risk.
